ANTI-WISP1 ANTIBODIES AND METHODS OF USE

Claims

This document provides antibodies and antibody fragments that specifically bind to WNT1-inducible signaling pathway 1 (WISP1) protein 1. The anti-WISP1 antibodies provided herein bind to domain 2 of the WISP1 protein and have been shown to inhibit WISP1 protein activity. Anti-WISP1 antibodies are considered effective for treating and preventing fibrosis in patients in need. Fibrosis is defined as either hepatic fibrosis or pulmonary fibrosis.

1. An antibody of the anti-WNT1 inducible signaling pathway 1 (WISP1) protein, comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises: a CDR H1 as set out in SEQ ID No. 1, a CDR H2 as set out in SEQ ID No. 2 and a CDR H3 as set out in SEQ ID No. 3; and wherein said light chain variable domain comprises: a CDR L1 as set out in SEQ ID No. 4, a CDR L2 comprising AAS, and a CDR L3 as set out in SEQ ID No. 6.